Preclinical and clinical development of immunocytokines

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 696-700

  Sondel, Paul M ^a,b   Hank, Jacquelyn A ^a,b   Gan, Jacek ^a,b   Neal, Zane ^a,b   Albertini, Mark R ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); Immunocytokine; Immunotherapy; Interleukin 2; Monoclonal antibody; Natural killer cells; T lymphocytes

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CYCLOPHOSPHAMIDE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14 18; MONOCLONAL ANTIBODY 14 18 INTERLEUKIN 2 HYBRID PROTEIN; MONOCLONAL ANTIBODY DISIALOGANGLIOSIDE 2; MONOCLONAL ANTIBODY KS INTERLEUKIN 2 HYBRID PROTEIN; MONOCLONAL ANTIBODY KS1 4; PACLITAXEL; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOXICITY; EFFECTOR CELL; GENETIC ENGINEERING; HUMAN; HYPOTENSION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MOLECULE; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; ONCOGENE NEU; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CYTOKINES; DRUG EVALUATION, PRECLINICAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0042666808     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90(6):2188-2195. Rituximab has proven to be an effective antitumor agent, proving that 22 years after the first creation of monoclonal antibodies, this technology has the potential as a clinically meaningful oncological application.
2. Harries M, Smith I: The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer (2002) 9(2):75-85.
3. Rosenberg SA: Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am (2000) 6(Suppl. 1):2-7. This brief review provides an overview on the development of IL-2, the first recombinant agent shown to induce measurable antitumor reactions by host immune cells against clinical cancers.
4. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung N-K, Sondel PM: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res (1990) 50(17):5234-5239.
5. Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM: Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and indomethacin. J Natl Cancer Inst (1988) 80(18):1451-1461.
6. Hank JA, Surfus J, Gan J, Chew T-L, Hong R, Tans K, Reisfeld R, Seeger R, Reynolds CP, Bauer M, Wiersma S et al: Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother (1994) 15(1):29-37. This study demonstrates that a combined treatment of IL-2 and anti-GD2 mAb induces NK function and ADCC activity that can be detected in vitro using serum from the patient as the only source of tumor-reactive mAb.
7. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD et al: Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.Ga plus IL-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group. Cancer (1997) 80(2):317-333.
8. Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH: Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol (1998) 16(6):2169-2180.
9. Gillies SD, Reilly EB, Lo K-M, Reisfeld RA: Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA (1992) 89(4):1428-1432. This is the first description of the immunological antitumor activity of hu14.18-IL-2, demonstrating function of its mAb and IL-2 components in vitro.
10. Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X, Lo KM, Lan Y, Super M, Gillies SD, Reisfeld RA: Elimination of established murine colon carcinoma metastases by antibody-interleukin-2 fusion protein therapy. Cancer Res (1997) 57(21):4948-4955.
11. Hank JA, Surfus JE, Gan J, Jaeger P, Gillies S, Reisfeld RA, Sondel PM: Activation of human effector cells by a tumor reactive recombinant anti-ganglioside-GD2/interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res (1996) 2(12):1951-1959.
12. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA: A recombinant antibody-interleukin-2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA (1994) 91(20):9626-9630.
13. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA: Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst (1997) 89(21):1586-1594. This is the first description of the antitumor action of hu14.18-IL-2 in vivo in a syngeneic tumor model, demonstrating that the antitumor activity depends on NK cells.
14. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA: Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood (1998) 91(5):1706-1715.
15. Neal Z, Rakhmilevich A, Hank J, Lode H, Reisfeld R, Gillies S, Sondel P: Hu14.18-IL2 immunocytokine plus systemic IL-2 combinatorial therapy: Prevention of tumor escape. Ann Sci Meet Soc Biol Ther (2002) 17:Poster 91.
16. Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM: The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res (2001) 61(4):1500-1507. Using variant subclones of a syngeneic colon cancer, these studies indicate that the level of H2 class I antigens on the tumor influence whether IC treatment eradicates metastases with T-cells or NK cells.
17. Algarra I, Cabrera T, Garrido F: The HLA crossroad in tumor immunology. Hum Immunol (2000) 61(1):65-73.
18. Kendra K, Gan J, Ricci M, Surfus J, Rakhmilevich A, Shaker A, Frost J, Hank J, Super M, Gillies S, Sondel P: Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother (1999) 48(5):219-229.
19. King D, Albertini M, Schalch H, Hank J, Surfus J, Gan J, Schiller JH, Mahvi D, Kim K, Reisfeld R, Dahl T et al: Phase I/IB trial of the immunocytokine hu14.18-IL-2 in patients with metastatic melanoma. Proc Am Soc Clin Oncol (2002) 21:Abs 62.
20. Hank JA, Albertini MR, Gan J, Surfus J, Sternberg A, Kind D, Schalch H, Kim K, Eickhoff J, Reisfeld RA, Gillies SD et al: Clinical administration of antibody-cytokine hu14.18-IL2 induces IL-2-mediated immune activation. Am Assoc Cancer Res (2003): in press.
21. Finke LH, Haunschild J, Kovar A, Dahl T, Gold D, Redfern C, Thompson T, Weber R, Bubley G, Gillies S: Early-phase clinical development of the immunocytokine EMD 273066 (huKS-IL2): Laboratory and safety findings in patients with prostate cancer. Ann Sci Meet Soc Biol Ther (2001) 16:Abs 8.
22. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD: Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res (2001) 7(9):2862-2869.
23. Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC: Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood (2002) 99(11):4166-4173.
24. Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, Super M, Lo KM: Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol (1998) 160(12):6195-6203. In vivo efficacy is demonstrated using an IC comprised of mAb and IL-12.
25. Gillies SD, Lo KM, Burger C, Lan Y, Dahl T, Wong WK: Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res (2002) 8(1):210-216.
26. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL: Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res (1999) 5(1):51-60.
27. Penichet ML, Dela Cruz JS, Shin SU, Morrison SL: A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies (2001) 10(1):43-49.